Diversified Trust Co reduced its stake in Johnson & Johnson (NYSE:JNJ) by 0.2% in the third quarter, HoldingsChannel reports. The institutional investor owned 42,951 shares of the company’s stock after selling 84 shares during the period. Diversified Trust Co’s holdings in Johnson & Johnson were worth $5,935,000 at the end of the most recent quarter.
A number of other hedge funds also recently added to or reduced their stakes in JNJ. Fundsmith Equity Fund L.P. bought a new position in shares of Johnson & Johnson during the second quarter valued at approximately $552,762,000. Peoples Financial Services CORP. increased its position in shares of Johnson & Johnson by 20.4% during the third quarter. Peoples Financial Services CORP. now owns 30,668 shares of the company’s stock valued at $4,237,000 after acquiring an additional 5,190 shares in the last quarter. Sather Financial Group Inc increased its position in shares of Johnson & Johnson by 3.7% during the second quarter. Sather Financial Group Inc now owns 11,051 shares of the company’s stock valued at $1,341,000 after acquiring an additional 399 shares in the last quarter. QUANTRES ASSET MANAGEMENT Ltd bought a new stake in shares of Johnson & Johnson during the third quarter valued at approximately $829,000. Finally, Foundation Resource Management Inc. bought a new stake in shares of Johnson & Johnson during the third quarter valued at approximately $208,000. 66.56% of the stock is owned by institutional investors.
Shares of JNJ stock opened at $137.60 on Monday. Johnson & Johnson has a 12-month low of $118.62 and a 12-month high of $148.99. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.20 and a current ratio of 1.47. The company has a market capitalization of $369.17 billion, a P/E ratio of 16.82, a P/E/G ratio of 2.13 and a beta of 0.68.
Johnson & Johnson announced that its Board of Directors has initiated a stock buyback program on Monday, December 17th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the company to buy up to 1.5% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s management believes its stock is undervalued.
The business also recently announced a quarterly dividend, which was paid on Tuesday, March 12th. Investors of record on Tuesday, February 26th were issued a $0.90 dividend. This represents a $3.60 annualized dividend and a yield of 2.62%. The ex-dividend date was Monday, February 25th. Johnson & Johnson’s dividend payout ratio is currently 44.01%.
Several equities research analysts recently weighed in on JNJ shares. Zacks Investment Research downgraded shares of Johnson & Johnson from a “hold” rating to a “sell” rating in a research report on Wednesday, January 16th. Citigroup reduced their price target on shares of Johnson & Johnson from $148.00 to $139.00 and set a “neutral” rating for the company in a research report on Wednesday, January 2nd. ValuEngine raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Thursday, December 13th. Wells Fargo & Co reissued an “outperform” rating and set a $152.00 price target (down previously from $162.00) on shares of Johnson & Johnson in a research report on Monday, January 14th. Finally, Barclays reissued an “equal weight” rating and set a $135.00 price target (down previously from $137.00) on shares of Johnson & Johnson in a research report on Wednesday, January 23rd. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and eight have assigned a buy rating to the stock. Johnson & Johnson presently has an average rating of “Hold” and a consensus target price of $142.81.
ILLEGAL ACTIVITY WARNING: This article was first published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.tickerreport.com/banking-finance/4229689/diversified-trust-co-decreases-position-in-johnson-johnson-jnj.html.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Read More: How to interpret a stock’s beta number
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.